<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04934150</url>
  </required_header>
  <id_info>
    <org_study_id>30-459-ex 17/18</org_study_id>
    <nct_id>NCT04934150</nct_id>
  </id_info>
  <brief_title>Neuronavigated Repetitive Transcranial Magnetic Stimulation (nrTMS) of the Dorsolateral Prefrontal and Primary Motor Cortex for the Treatment of Chronic Pain</brief_title>
  <official_title>Neuronavigated Repetitive Transcranial Magnetic Stimulation (nrTMS) of the Dorsolateral Prefrontal and Primary Motor Cor-tex for the Treatment of Chronic Pain: a Randomized Place-bo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Graz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigated the effects of navigated repetitive Transcranial Magnetic Stimulation&#xD;
      on nociception and quality of life in patients suffering from chronic pain conditions. Two&#xD;
      cortical targets (dorsolateral prefrontal cortex/DLPFC and M1 area) were stimulated and&#xD;
      compared to Sham stimulation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      From 34 patients, 24 completed the study. The M1-area was stimulated with 10 Hz rTMS while&#xD;
      the DLPFC received a 5Hz stimulation. In total, 13 session were administered over a period of&#xD;
      36 weeks with most frequent stimulation in the first 4 weeks of the trial. Results were&#xD;
      compared to Sham-TMS over the M1 area at the same schedule than the actual therapy. Outcome&#xD;
      parameters included the German Pain Questionnaire (GPQ), the Depression, Anxiety and Stress&#xD;
      Scale&quot; (DASS) and quality of life (QoL) with the SF-12 questionnaire.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2019</start_date>
  <completion_date type="Actual">October 30, 2020</completion_date>
  <primary_completion_date type="Actual">March 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The study was conducted in a single-blinded, randomized, placebo-controlled design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Sham stimulation was provided by turning the TMS coil to the non-stimulating side.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Numeric Rating Scale</measure>
    <time_frame>36 weeks</time_frame>
    <description>0-10 0 = no pain, 10 = worst pain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Self-reported &quot;Depression, Anxiety and Stress Scale&quot; (DASS) questionnaire.</measure>
    <time_frame>36 weeks</time_frame>
    <description>0- 21 for each item, higher scores indicate worse symptoms. Lower scores indicate a better outcome</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Chronic Pain</condition>
  <arm_group>
    <arm_group_label>M1 stimulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 Hz stimulation of left motor area</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DLPFC stimulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5 Hz stimulation of left dorsolateral prefrontal cortex</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham TMS</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham TMS over the left M1 area</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>navigated repetitive Transcranial Stimulation</intervention_name>
    <description>High frequency nrTMS over 13 sessions (1800-2000 pulses per session) over DLPFC and M1 cortical areas.</description>
    <arm_group_label>DLPFC stimulation</arm_group_label>
    <arm_group_label>M1 stimulation</arm_group_label>
    <arm_group_label>Sham TMS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age between 18 and 80 years&#xD;
&#xD;
          -  clinical diagnosis of chronic LBP (low back pain) and or neck pain&#xD;
&#xD;
          -  average resting pain-level &gt; than 3 in the Numeric Rating Scale (0-10)&#xD;
&#xD;
          -  no changes in pain medication 4 weeks at baseline&#xD;
&#xD;
          -  no surgical procedures in the last 2 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  metallic and electronic implants in the head, neck and chest&#xD;
&#xD;
          -  medication e.g. tetracyclic antidepressants, antiviral, antipsychotic, opioid doses &gt;&#xD;
             100mg orally/d&#xD;
&#xD;
          -  history of frequent headache or tinnitus&#xD;
&#xD;
          -  alcohol or drug abuse&#xD;
&#xD;
          -  pregnant patients&#xD;
&#xD;
          -  breastfeeding patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medical University Graz</name>
      <address>
        <city>Graz</city>
        <state>Styria</state>
        <zip>8010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 14, 2021</study_first_submitted>
  <study_first_submitted_qc>June 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 22, 2021</study_first_posted>
  <last_update_submitted>June 28, 2021</last_update_submitted>
  <last_update_submitted_qc>June 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

